Distance-Based All-In-One Immunodevice for Point-of-Care Monitoring of Cytokine Interleukin‑6
Journal article
Authors/Editors
Strategic Research Themes
Publication Details
Author list: Kawin Khachornsakkul, Wijitar Dungchai and Nicole Pamme
Publisher: American Chemical Society
Publication year: 2022
Journal: ACS Sensors (23793694)
Volume number: ึ7
Issue number: 8
Start page: 2410
End page: 2419
Number of pages: 10
ISSN: 23793694
eISSN: 2379-3694
URL: https://pubs.acs.org/doi/10.1021/acssensors.2c01122
View in Web of Science | View on publisher site | View citing articles in Web of Science
Abstract
We report the development of a distance-based paper analytical device combined with a hydrophilic bridge valve (BdPAD) as a quantitative immunoassay method to monitor human interleukin-6 (IL-6) in human samples. Our device design features (i) a circular sample inlet zone, (ii) a circular capture zone with immobilized anti-IL-6 (anti-Ab1), and (iii) a detection zone channel coated with methylene blue (MB). Two hydrophilic valves are positioned between these three zones. IL-6 levels were determined quantitatively by measuring the extent of degradation of MB to a colorless product along the length of the detection zone channel. Following method optimization, we obtained a linear range from 0.05 to 25.0 pg/mL (R2 = 0.9995) and a detection limit (LOD) of 0.05 pg/mL by the naked-eye readout. This is directly within the clinically relevant range. The system does not require any external instrumentation, and the bridge valves can be easily connected and disconnected by a minimally trained operator. The total analysis time is 35 min, significantly reduced from a typical ELISA assay, which takes around 1 h since the B-dPAD workflow circumvents washing steps. The device was tested for IL-6 quantification in human saliva and urine samples of volunteers, with no significant difference found between our method and the standard clinical laboratory method at 95% confidence levels. Recoveries ranged from 98 to 105% with the highest standard deviation at 3.9%. Our B-dPAD immunodevice is therefore a promising approach for rapid IL6 monitoring in the context of point-of-care diagnostics and analysis in resource-limited settings.
Keywords
No matching items found.